Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 2

	control information unless it contains a valid OMB control number				
		Complete if Known			
	The second statistics	UNKNOWN	_	١	
ı	Filing Date	CONCURRENTLY HEREWITH			
ŀ	First Named Inventor	Rafael Herrmann et al.		Į	
ŀ	Group Art Unit	UNKNOWN	0	į	
4	Examiner Name	UNKNOWN	2;	ı	
L	Attorney Docket Number	BB1367 US CNT	<u> </u>	ŀ	
_		C COUNT	乄	•	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	_	
Examiner Initials *	Cite No.	the item (book, magazine, journal, social, serial, social, serial, ser		
87	1	number(s), publisher, city and/or country where published. J. M. SABATIER ET AL., Int. J. Peptide Protein Res., vol. 43:486-495, 1994, Leiurotoxin I, a Scorpion Toxin Specific for Ca2+-activated K+ Channels	\downarrow	
	2	ELIAHU ZLOTKIN, Phytoparasitica, vol.19(3):177-183, 1991, Venom Neurotoxins - Models for Selective	L	
	3	BAKBARA SELISKO ET AL E	L	
	4	Noxius Hoffmann constitute a Subfamily of Potassium-channel-blocking Scorpion Toxins FATIMA LARABA-DJEBARI ET AL., Journ. of Biol. Chem., vol. 269(52):32835-32843, 1994, The Kaliotoxin Family Enlarged	_	
	5	ERIC BUISINE ET AL., J. Peptide Res., vol. 49:545-555, 1997, Characterization of a New Family of Toxin-Like JOSE C. MARTINS ET AL. 5000		
	6	JOSE C. MARTINS ET AL., FEBS Letters, vol. 260(2):249-253, 1990, Solution Conformation of Leiurotoxin I LP ROSS EX AL.		
	7	J.P. ROSS ET AL., Toxicon, vol. 23(1):113-125, 1985, Characterization of Ten Porteins from the Venom of the D. L. MARSHALL ET AL., Toxicon, vol. 20(4):1		
	8	D. L. MARSHALL ET AL., Toxicon, vol. 32(11):1433-1443, 1994, Neuromuscular Effects of Communication of Commu		
	9	E. ZLOTKIN ET AL., Archives of Biochem. and Biophys., vol. 240(2):877-887, 1985, An Excitatory and a Site		
	10	E. ZLOTKIN ET AL., Biochimie, vol. 53:1073 1079 1079		
4	11	Venom of the Scorpion Androctonus Australis Hector National Center for Biotechnology Information General Identifier No. 2959750, 8/5/98		

			2000/30, 6/5/98	l l
Examiner Signature	9. Soldberg	Date		
		10-	3/25/03	
considered. Include	if reference considered, whether or not citation is in co	nformance with MPEP 609 Draw	y line at	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,





¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.





Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use

e as many she	ets as	nec	essary)
2	of	2	

	and matter unless it contains a valid OMB control number	er e
	Complete if Known	70
Application Number	UNKNOWN	- 6
Filing Date	CONCURRENTLY HEREWITH	
First Named Inventor	Pafael Hammer HEREWITH	EQ
Group Art Unit	Rafael Herrmann et al.	2
Examiner Name	UNKNOWN	Ti
	UNKNOWN	0
Attorney Docket Number	BB1367 US CNT	~

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examine Initials *	No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7
4/	 1	National Center for Biotechnology Information General Identifier No. 1173377, 2/1/96	
	2	National Center for Biotechnology Information General Identifier No. 1711347, 5/30/00	
	National Center for Biotechnology Information General Identifier No. 1711349, 5/30/00 National Center for Biotechnology Information General Identifier No. 134302, 10/1/00		
	5	GARY G. CHIOCHI ET AL., Journ. of Biol. Chem., vol. 263(21):10192-10197, 1988, Purification and Characterization of a Unique, Potent Inhibitor of Apamin Binding from Leiurus Quinquestriatus Hebraeus Venom	
ļ	6 PATRICK AUGUSTE ET AL., Journ. of Biol. Chem., vol. 265(8):4753-4759, 1990, Leiurotoxin I (Scyllatoxin), a Peptide Ligand for Ca2+-activated K+ channels		
-	7	National Center for Biotechnology Information General Identifier No. 134379, 11/1/95	
	8	National Center for Biotechnology Information General Identifier No. 1173380, 11/1/95	
	9	National Center for Biotechnology Information General Identifier No. 4389290, 6/16/98	
	10	ERIC BLANC ET AL., Biochemistry, vol. 37:12412-12418, 1998, Solution Structure of Two New Toxins from the Venom of the Chinese Scorpion Buthus Martensi Karsch Blockers of Potassium Channels	
4	11	MARIA L. GARCIA ET AL., Biochemistry, vol. 33:6834-6839, 1994, Purification and Characterization of Three Inhibitors of Voltage-Dependent K+ Channels from Leiurus quinquestriatus var. hebraeus Venom	

Examiner				
Signature	S. Soldberg	Date	2/24/02	
EXAMINER: Initial	if reference considered, whether or not citation is in conf	Considered	<u>3</u> (24 (03	
considered. Include	copy of this form with a sector or not citation is in conf	Ofmance with MPED coo. o		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,







¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.





PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

or a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

	or Information unless it contains a valid OMB control num Complete if Known	ider.
Application Number	UNKNOWN	
Filing Date	CONCURRENTLY HEREWITH	_
First Named Inventor	Rafael Herrmann et al.	<u> </u>
Group Art Unit	UNKNOWN	-6-
Examiner Name	UNKNOWN	
Attorney Docket Number	BB1367 US CNT	-

	J	U.S. Pate	ent Document	U.S. PATENT DOCUM	MENTS	
xaminer Initials *	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relev Passages or Relevant Figures Appear
व्य	1	4,925,66	4	Inglia	MM-DD-YYYY	Figures Appear
				Jackson et al.	05/15/90	
					<u>`</u>	

F		For	eign Patent Do	FOREIG	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Office ³	Number ⁴	Kind Code ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
2		World	95/03065	(if known)	Merck & Co., Inc.	MM-DD-YYYY	Passages or Relevant Figures Appear	Τe
&		Europe	0 374 753		Ciba-Geigy AG	02/02/1995 12/15/1989		
89		World	94/28114		American Cyanamid Company	12/8/1994		
				-				
				+				
				 -				

				1
Examiner Signature	& Goldberg	Date	2/25/25	
EXAMINER: Initial considered, Include	if reference considered, whether or not citation is in	Considered	3/25/03	

AINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a